FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Autoimmune Diseases topics
Immune Diseases
Autoimmune Disease
Autoimmune Diseases
Immune Disease
Autoimmune
Rheumatoid Arthritis
Antibodies
Proliferative
Nucleotide
Antagonist
Infectious Diseases
Inflammatory Disease
Infectious Disease
Infectious
Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Diseases patents



      
           
This page is updated frequently with new Autoimmune Diseases-related patent applications. Subscribe to the Autoimmune Diseases RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune Diseases RSS RSS


Date/App# patent app List of recent Autoimmune Diseases-related patents
05/21/15
20150141523
 Compounds for use in the treatment of autoimmune inflammatory disease patent thumbnailnew patent Compounds for use in the treatment of autoimmune inflammatory disease
And salts thereof is useful in the prophylaxis or treatment of inflammatory bowel disease or other inflammatory autoimmune diseases with similar aetiology involving t-cell proliferation or or function.. .
05/21/15
20150141397
 Substituted anilines as ccr(4) antagonists patent thumbnailnew patent Substituted anilines as ccr(4) antagonists
Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.
05/21/15
20150141328
 Stimulation of human meibomian gland function patent thumbnailnew patent Stimulation of human meibomian gland function
Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a pld-inducing compound, such as the cationic amphiphilic drugs (e.g. Azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, igf-1 or an igf-1 analogue (e.g.
The Schepens Eye Research Institute
05/21/15
20150140085
 Formulations comprising ibrutinib patent thumbnailnew patent Formulations comprising ibrutinib
Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.. .
Principia Biopharma Inc.
05/14/15
20150132788
 Establishing the viability of biological samples patent thumbnailEstablishing the viability of biological samples
The invention relates to a method, a use and a kit for establishing the viability (ability to live) of biological samples using ageladine a. The invention is advantageously suitable for establishing the viability of biological samples which can otherwise be dyed in an intra-cellular manner by fluorescence dyes other than ageladine a not at all or only with difficulty.
05/14/15
20150132369
 Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof patent thumbnailNanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as cyclosporine a, and the method of preparing the same. The reduced toxicity and significant reduction of delayed-type hypersensitivity dth) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention..
05/14/15
20150132326
 Immunosuppressive blood cells and methods of producing the same patent thumbnailImmunosuppressive blood cells and methods of producing the same
The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .
05/14/15
20150132312
 Systems and methods for extracorporeal blood modification patent thumbnailSystems and methods for extracorporeal blood modification
The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject.
05/07/15
20150125880
 Methods for induction of antigen-specific regulatory t cells patent thumbnailMethods for induction of antigen-specific regulatory t cells
The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory t cells in vitro or in vivo.
Katholieke Universiteit Leuven
05/07/15
20150125536
 Methods and compositions for sustained immunotherapy patent thumbnailMethods and compositions for sustained immunotherapy
This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of tr1 cells and/or breg cells in an antigen-specific manner and treating autoimmune diseases and disorders in a subject in need thereof.. .
Uti Limited Partnership
05/07/15
20150125460

Anti-bcma antibodies


This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Idec Ma Inc.
05/07/15
20150125390

18f-labelled folate/antifolate analogues


The present invention is directed towards new 18f-folate/antifolate analogue radiopharmaceuticals, wherein the phenyl group within folate structures has been replaced by an 18f-heterocycle, their precursors, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie
04/30/15
20150118318

Methods of treating inflammatory and autoimmune diseases and disorders


Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder.
Yale University
04/30/15
20150118264

Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen


The present invention is directed to a pharmaceutical composition including (e.g. For use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh
04/30/15
20150118259

28 kda gst proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a th1 and/or th17 response


The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kda glutathione s-transferase protein from a schistosome selected from schistosoma haematobium, schistosoma mansoni, schistosoma bovis represented respectively by the sequences seq id no: 1, seq id no: 2 and seq id no: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type th1 and/or th17.. .
Centre Hospitalier Regional Universitaire De Lille
04/30/15
20150118183

Negatively charged nucleic acid comprising complexes for immunostimulation


The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. Peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh
04/23/15
20150111873

Pharmaceutically active pyrazolo-triazine derivatives


Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh
04/23/15
20150111872

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .
04/23/15
20150111835

Modified peptides and their use for treating autoimmune diseases


The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications.. .
Centre National De La Rechereche Scientifique
04/23/15
20150110805

Therapeutic strategy for treating autoimmune and degenerative diseases


Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases.
Immunaid Pty Ltd.
04/16/15
20150104866

Ip-10 antibodies and their uses


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.
04/09/15
20150099770

Carboxylic acid compounds


The present disclosure concerns at least one entity chosen from compounds of formula (i) and pharmaceutically acceptable salts thereof: (i) wherein the variable groups x, r1, r2, r3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer..
Astrazeneca Aktiebolag
04/09/15
20150099001

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
Massachusetts Institute Of Technology
04/09/15
20150098955

Cd40l-specific tn3-derived scaffolds and methods of use thereof


The present invention provides tenascin-3 fniii domain-based scaffolds that specifically bind to cd40l. The invention further provides engineered variants with increased affinity for the target.
Medlmmune, Llc
04/02/15
20150094319

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
04/02/15
20150093799

Histidyl-trna synthetases for treating autoimmune and inflammatory diseases


The present invention relates generally to compositions and methods comprising histidyl-trna synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to jo-1 antibodies.. .
Atyr Pharma, Inc.
03/26/15
20150087643

Substituted fused pyrimidine compounds


The present invention discloses substituted fused pyrimidine compounds of formula (i), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (ar) activity; the compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.. .
Advinus Therapeutics Private Limited
03/26/15
20150087620

Amine compound and use thereof for medical purposes


Wherein each symbol is as described in the description, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (gvh) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.. .
03/26/15
20150087529

Sequencing analysis of circulating dna to detect and monitor autoimmune diseases


Systems, methods, and apparatuses are provided for diagnosing auto-immune diseases such as systemic lupus erythematosus (sle) based on the sizes, methylation levels, and/or genomic characteristics of circulating dna molecules. Patients provide blood or other tissue samples containing cell-free nucleic molecules for analysis.
The Chinese University Of Hong Kong
03/19/15
20150080391

Novel compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders


The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and their use in the prophylaxis and/or treatment of inflammatory conditions, type 2 diabetes, neurological and/or neurodegenerative diseases, autoimmune diseases, proliferative diseases (in particular metastatic diseases, and/or cancer), abnormal angiogenesis associated diseases, degradation of cartilage, and/or disruption of cartilage homeostasis, in particular in the prophylaxis and/or treatment of cancer. The present invention also discloses methods of treatment using the same compounds, for the prophylaxis and/or treatment of said diseases by administering the compound of the invention..
03/19/15
20150080369

Novel compounds


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited
03/19/15
20150080356

Method for improving therapy for autoimmune diseases such as rheumatoid arthritis


In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases.
Toyama Chemical Co., Ltd.
03/12/15
20150072986

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.
03/12/15
20150072980

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc
03/12/15
20150072978

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.
03/05/15
20150065507

Novel compounds


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited
02/26/15
20150057297

Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions


The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, t-cell neoplasms, and cosmetic conditions..
The General Hospital Corporation D/b/a Massachusetts General Hospital
02/26/15
20150056198

Aberrant cell-restricted immunoglobulins provided with a toxic moiety


Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.
02/26/15
20150056185

Immunoglobulin constant region fc receptor binding agents


Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
University Of Maryland, Baltimore
02/19/15
20150051242

Rafamycin analogs and methods for making same


A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mtor inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal.
Zhejiang Zylox Medical Device Co., Ltd.
02/19/15
20150051196

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
02/19/15
20150051178

Estriol therapy for autoimmune and neurodegenerative diseases and disorders


The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period..
The Regents Of The University Of California
02/19/15
20150050210

Pharmaceutical formulation comprising bendamustine


The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives.
Salmon Pharma Gmbh
02/12/15
20150045361

Heterocyclic compounds and their uses


Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.
02/12/15
20150045324

Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity


The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.. .
Hanmi Science Co., Ltd
02/12/15
20150044244

Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases


The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing a vaccine facilitator comprising a na/k pump inhibitor, an antigen and a dna encoding the antigen.. .
Beijing Advanccine Biotechnology Co. Ltd.
02/12/15
20150044164

Methods of treating autoimmune diseases


Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells.
Genzyme Corporation
02/12/15
20150044134

Compositions, methods and kits for treatment of cancer and autoimmune diseases


The present invention is directed to fusion proteins having an il-21 cytokine portion and an anti-cd20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the il-21-anti-cd20 fusion proteins.
University Of Miami
02/05/15
20150038545

Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof


As well as to the procedure for their preparation, pharmaceutical compositions comprising the same and the use thereof for the treatment and/or prevention of a condition mediated by histone deacetylase such as cancer, hematological malignancies, autoimmune diseases, inflammatory diseases, diseases of the central nervous system (cns) such as neurodegenerative diseases and psychiatric disorders, cardiovascular diseases, endocrine and metabolic disorders, by inhibiting histone deacetylases and the therapeutic use of biological processes related to the mentioned inhibition.. .
02/05/15
20150038538

Thiadiazolidinediones as gsk-3 inhibitors


The present invention relates to new thiadiazolidinediones of formula (i), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (gsk-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them..
Asd Therapeutics Partners Llc
02/05/15
20150038480

Compounds that modulate autoimmunity and methods of using the same


The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same..
The Regents Of The University Of Colorado, A Body Corporate
02/05/15
20150037886

Treatment drug for autoimmune diseases and allergic diseases


The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-embigin antibody, particularly an anti-embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving th17 cell, and a cytotoxic agent to th17 cell. In addition, an agent for detection of th17 cell, which contains an anti-embigin antibody, a convenient detection method of th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a th17 cell selective manner, which uses an anti-embigin antibody, and a drug delivery system to th17 cell are provided..
Sumitomo Dainippon Pharma Co., Ltd.
01/29/15
20150031706

Novel compound useful for the treatment of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..
01/29/15
20150031671

Novel compound useful for the treatment of degenerative and inflammatory diseases


This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
01/22/15
20150023976

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited
01/15/15
20150018336

Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
01/15/15
20150018329

Pharmaceutically active pyrazolo-triazine derivatives


The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh
01/15/15
20150017164

Combination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease


The invention relates to novel combination therapies involving blys or blys/april inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the blys and/or april antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Ares Trading S.a.
01/15/15
20150017132

Mesenchymal stem cells and uses therefor


Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl
01/08/15
20150011767

Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints


The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University
01/08/15
20150010588

Aromatic-cationic peptides and uses of same


The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport, inhibition of cardiolipin peroxidation, and inhibition of apoptosis and necrosis to treat, prevent or ameliorate the symptoms of autoimmune diseases or condition..
Cornell University
01/01/15
20150004178

Anti-human sema4a antibodies useful to treat disease


Anti-human sema4a antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4a antibodies can inhibit t cell proliferation and th2 differentiation induced by il-4, anti-cd3, anti-cd28 and recombinant sema4a..
Board Of Regents, The University Of Texas System
12/25/14
20140378475

Substituted tetrahydrocarbazole and carbazole carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140378446

Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
12/25/14
20140377291

Glycosphingolipids for use in modulating immune responses


Provided herein are sphingolipid compounds that are useful for activating natural killer t cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer t cells.
President And Fellows Of Harvard College
12/18/14
20140371272

Therapeutic compounds


The invention provides compounds of formula (i) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (i), processes for preparing compounds of formula (i), intermediates useful for preparing compounds of formula (i) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (i)..
Regents Of The University Of Minnesota
12/18/14
20140371242

Azathioprine oral suspensions and methods of use


Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
12/18/14
20140371198

Novel compounds useful for the treatment of metabolic and inflammatory diseases


These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.. .


Popular terms: [SEARCH]

Autoimmune Diseases topics: Immune Diseases, Autoimmune Disease, Autoimmune Diseases, Immune Disease, Autoimmune, Rheumatoid Arthritis, Antibodies, Proliferative, Nucleotide, Antagonist, Infectious Diseases, Inflammatory Disease, Infectious Disease, Infectious, Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         















0.8124

3957

459292 - 0 - 72